Eupraxia Pharmaceuticals Inc.

EPRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.64

+$0.06 (+0.70%)

At close: Sep 21, 2026, 4:00 PM ET

$8.64

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $289.27M

Enterprise Value $157.71M

Beta 1.50

Average Volume 374.52K

Shares Outstanding (Diluted) 66.22M

Shares Change YoY 84.4%

Institutional Ownership 39.20%

Exchange NASDAQ

ISIN CA29842P1053

Price Performance

Price Change 1M 27.6%

Price Change 3M 35.2%

Price Change 6M 22.0%

Price Change YTD 14.1%

Price Change 1Y 29.9%

Price Change 3Y 192.9%

Price Change 5Y 192.9%

1M CAGR (ann.) 27.6%

1Y CAGR (ann.) 43.0%

5Y CAGR (ann.) N/A

All-Time CAGR 54.7%

Valuation

PE Ratio -8.39

Forward PE N/A

PEG Ratio 0.38

Forward PEG -0.59

PS Ratio N/A

Forward PS 20.60

PB Ratio 2.21

P/FCF Ratio -7.84

P/Adj. FCF Ratio -7.77

P/OCF Ratio -16.00

EV/Sales N/A

EV/EBIT -3.26

EV/EBITDA -3.27

EV/FCF -4.27

Earnings Yield -11.9%

FCF Yield -12.8%

Adj. FCF Yield -12.9%

Financial Health

Net Cash $133.4M

Total Debt $1.84M

Cash & Short-Term Investments $133.4M

Total Assets $139.64M

Current Ratio 16.00

Quick Ratio 16.00

Debt / Equity Ratio 0.01

Debt / EBITDA -0.04

Debt / FCF -0.05

OCF / Debt -19.67

Interest Coverage 0.00

Altman Z-Score 14.98

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -0.9%

Returns

Return on Assets -35.7%

Return on Equity -45.3%

Return on Invested Capital -43.1%

Return on Capital Employed -43.2%

Return on Tangible Assets -35.7%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -21.4%

EPS CAGR 5Y 7.2%

EPS CAGR 10Y N/A

FCF CAGR 3Y -28.2%

FCF CAGR 5Y -22.8%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 2

EPS Growth Next 3Y -27.9%

Revenue Growth Next 3Y N/A

Earnings Date Nov 2, 2026

EPS Estimate (next Q) -$0.27

EPS Growth Est (next Q) 42.1%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $17

Price Target Upside 96.8%

Cash Flow

Operating Cash Flow $-36.18M

Free Cash Flow $-36.92M

Adj. Free Cash Flow $-37.24M

FCF Per Share -$0.55

OCF Per Share -$0.54

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-193.79K

Operating Income $-56.65M

EBITDA $-48.26M

Net Income $-48.38M

EPS (Diluted) -$1.03

Revenue / Employee N/A

Profit / Employee $-987.44K

Employees 49